A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

NCT ID: NCT06655870

Last Updated: 2026-01-20

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-31
• Study Completion Date: 2026-06-23

Brief Summary

The purpose of this study is to test the safety of mRNA-0184 in healthy participants.

Conditions

Healthy Participants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Single Ascending Dose (SAD): mRNA-0184

Participants will receive a single subcutaneous (SC) injection of a fixed dose of mRNA-0184 on Day 1.

Group Type: EXPERIMENTAL

mRNA-0184

Intervention Type: DRUG

SC injection

Multiple Ascending Dose (MAD): mRNA-0184

Participants will receive up to 2 SC injections of a fixed dose of mRNA-0184 on Days 1 and 15.

Group Type: EXPERIMENTAL

mRNA-0184

Intervention Type: DRUG

SC injection

Interventions

mRNA-0184

SC injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiogram (ECG), and vital signs.
• Body weight within 50 to 100 kilograms (kg) (inclusive) and body mass index within 18 to 32 kg/square meter (m^2) (inclusive) at Screening.
• Participant who could become pregnant must meet conditions as defined in the protocol.

Exclusion Criteria

• History of any clinically significant disease or disorder, including bleeding disorders and wound healing disorders, which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
• Any clinically significant illness, or medical/surgical procedure, within 4 weeks of the first administration of the study drug (mRNA-0184).
• Any clinically significant abnormalities in clinical laboratory results at Screening. Repeat assessments are allowed at the Investigator's discretion if a false positive is suspected.
• Clinically significant abnormal findings in vital signs at Screening.
• Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.
• Use of any prescribed medication or over-the-counter (OTC) medication that may have an impact on the interpretation of study analyses in the opinion of the Investigator during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of the study drug. Such prescribed or OTC medications are also not permitted during participation in the study. Hormonal contraception is permitted.
• Participation in another clinical study of another drug product (DP) within 30 days before Screening or within 5 terminal half-lives of the DP, whichever is longer.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

ModernaTX, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Nucleus Network

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

mRNA-CRTX-002

Identifier Type: -

Identifier Source: org_study_id